Medtech Startups: Ivantis, Wellinks, Innoventric, & more

Posted by Life Science Intelligence on Nov 10, 2021 7:34:59 AM
Find me on:

Last week, medtech startups raised approximately $443.4M in funding across 12 deals, in addition to other undisclosed deals that were announced.


Below are some of the top deals tracked over the past week:

Start a Free Trial to Medtech Startup Tracker Today

Top Deals – Medtech Fundraising Transactions for the Week



Amount Raised


Edge Medical Robotics

Minimally invasive robotic surgery platform


Series C


Needle-free continuous glucose monitor


Series B

Beacon Biosignals

EEG neurobiomarker discovery platform


Series A

Top deals for the week are based on publicly available information. At this time of this article’s publication, new deals for the week may have been announced.


LSI's Medtech Startup Tracker is focused exclusively on covering the innovators changing the medical device landscape. Here are some of the interesting startups we’ve recently profiled:

Ivantis to be acquired by Alcon

On November 8th, 2021, Alcon announced that it intends to acquire Ivantis in a deal valued at $475M. Ivantis is a developer of the Hydrus microstent, a minimally invasive surgical solution for the treatment of open-angle glaucoma. Ivantis’ Hydrus received regulatory approval from the FDA in August 2018 for the treatment of primary open-angle glaucoma during cataract surgery, or as a standalone procedure. According to Ivantis CEO Dave van Meter, more than 85,000 Hydrus stents have been implanted globally. The acquisition is expected to be completed in Q1 2022.


Wellinks closes $25M Series C investment

The investment will be used to expand Wellinks’ virtual management solution for chronic obstructive pulmonary disease (COPD). The platform captures health measures using the company’s nebulizer, spirometer, and pulse oximeter devices to provide patients with personalized insights and management strategies for their disease. Patients can virtually access personalized coaching, education, and motivational support for the management of their disease. With the close of this recent investment, the company has raised an estimated $43M in total funding.


Innoventric raises $16.9M from Series A and Grant

Innoventric is developing a next-generation solution for the treatment of tricuspid regurgitation. Current tricuspid valve replacement techniques face a variety of complications, including device migration and continued valvular leaking. Innoventric’s Trillium device features a cross-caval anchoring system and multi-valve design to treat tricuspid regurgitation without the limitations of alternative treatment approaches. Trillium has been successfully implanted in 10 patients as part of its first-in-human clinical trial. The grant was awarded through the prestigious Horizon Europe program, which identifies top companies with groundbreaking technologies. Key strategics in the structural heart disease management market include Abbott, Edwards, and Medtronic.


Aktiia – simplifying blood pressure monitoring

Aktiia’s wearable blood pressure monitor provides patients and doctors with continuous blood pressure monitoring data from an inobtrusive bracelet. The device, which is commercially available in Europe for approximately £189 (~$250), measures blood pressure hourly for up to nine days on a single charge. The company recently raised $17.5M in Series A funding. Funds from the round will be used to obtain regulatory clearance in the US and expand the commercial presence of the company’s continuous blood pressure monitoring device in Europe. To date the company has raised $27.8M in capital.


Neuron Guard is developing a device to prevent acute brain damage

Stroke, sudden cardiac death, and traumatic brain injury all present a risk of disability and reduced quality of life due to acute brain damage (ABD). Neuron Guard is developing a medical device that utilizes cooling and infusion technology to reduce the progression of ABD in patients experiencing acute neurological incidents. The device, which is fitted around patients with a collar-like device, is being evaluated for multiple applications to prevent the progression of ABD that causes loss of functions. Neuron Guard recently announced that they have raised $1.4M from a Seed round in November 2021.


New View Surgical – an integrated handpiece for laparoscopic surgery

The VisionPort system is a laparoscopic handpiece that combines the access port, camera, light source, and laparoscope into a single device. The device simplifies the capital equipment required for performing minimally invasive surgery – making MIS more affordable and efficient. The VisionPort system obtained FDA clearance in June 2021. On November 2nd, 2021, New View Surgical announced the completion of a Series B round which brought in $9M from 8 investors, including lead investor New York Angels. Karl Storz, Olympus, and Stryker are some of the leading strategics in the MIS surgery market.  


Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.

Topics: Insider, Startup, Strategics, Medtech

Stay connected with our latest posts:

About the Author

Life Science Intelligence (LSI) helps medtech executives make better strategic decisions by delivering unique market data and business insights. For over 13 years LSI has been working with industry giants – Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal, Boston Scientific, and Becton Dickinson, among others. LSI products are also leveraged by the most successful start-ups, innovators, investors, and service companies that compete in medtech. LSI is the organizer of The Emerging Medtech Summit held annually in Southern California.

Contact LSI here, via phone 714 847 3540, or email